Novelion Therapeutics Inc. Stock price

Equities

NVLNF

CA67001K2020

Delayed OTC Markets 5-day change 1st Jan Change
- USD -.--% Intraday chart for Novelion Therapeutics Inc. -4.49% -0.54%
Sales 2017 138.44 Sales 2018 130.43 Capitalization 15.9M
Net income 2017 -127M Net income 2018 -108M EV / Sales 2017 1,887,512 x
Net Debt 2017 203M Net Debt 2018 303M EV / Sales 2018 2,447,567 x
P/E ratio 2017
-0.46 x
P/E ratio 2018
-0.15 x
Employees -
Yield 2017 *
-
Yield 2018
-
Free-Float 0%
More Fundamentals * Assessed data
Dynamic Chart
Novelion Therapeutics Inc, formerly QLT Inc., is a Canada-based biopharmaceutical company. The Company is engaged in development of new standards of care for individuals living with rare diseases. The Company is focused on advancing its portfolio of rare disease therapies by investing in science and clinical development. The Company holds a portfolio of products through its subsidiary, Aegerion Pharmaceuticals, Inc., a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare diseases. The Company's portfolio of products include MYALEPT and JUXTAPID. The Company is also developing zuretinol acetate for the treatment of inherited retinal disease caused by underlying mutations in RPE65 or LRAT genes.
Sector
-
More about the company
  1. Stock
  2. Equities
  3. Stock Novelion Therapeutics Inc. - OTC Markets